Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSPO | P30536 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403929 | 0.93 | TSHR (0.62) | TSHRMAPK1PPARGHDAC1HDAC6 | |
| SCHEMBL5402850 | 0.92 | MEN1 (0.46) | TSHRMAPK1LPAR1LTB4R2LMNA | |
| SCHEMBL5399607 | 0.91 | LTB4R2 (0.56) | HDAC1HDAC6LPAR1LTB4R2LMNA | |
| SCHEMBL5398893 | 0.90 | KMT2A (0.56) | LPAR1LMNA | |
| SCHEMBL5397925 | 0.89 | GAA (0.50) | TSHRHDAC1HDAC6LPAR1LTB4R2 | |
| SCHEMBL5402854 | 0.86 | TDP1 (0.59) | TSHRMAPK1PPARGHDAC1HDAC6 | |
| SCHEMBL5392691 | 0.86 | TSHR (0.56) | TSHRMAPK1PPARGHDAC1HDAC6 | |
| SCHEMBL5399681 | 0.85 | KMT2A (0.54) | HDAC1HDAC6LMNA | |
| SCHEMBL5398638 | 0.85 | KMT2A (0.54) | HDAC1HDAC6LMNA | |
| SCHEMBL5405911 | 0.85 | TSHR (0.55) | TSHRMAPK1PPARGLPAR1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | TSHR 3382/4885MAPK1 1369/4885PPARG 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.